1.0	delivery	devices
0.5	ards	and
1.0	using	standard
0.125	.	nine
0.5	on	currently
0.25	,	ventilator-free
0.5	ali	or
1.0	based	on
1.0	consistent	end
1.0	effects	.
0.14285714285714285	in	the
1.0	conditions	associated
1.0	treatment	of
1.0	reporting	on
0.5	clinical	application
1.0	epoprostenol	(aepo)
0.125	.	this
0.3333333333333333	aepo	were
0.14285714285714285	in	disease
0.14285714285714285	the	clinical
1.0	estimated	mortality
0.125	of	either
0.14285714285714285	in	patients
0.2	and	aerosolized
1.0	an	estimated
1.0	(ali)	are
1.0	hemodynamic	effects
1.0	nitric	oxide
1.0	severity	.
0.5	on	changes
1.0	currently	available
1.0	devices	and
1.0	been	observed
0.2	to	use
1.0	observed	in
1.0	addition	,
0.5	associated	with
0.5	ali	.
1.0	benefit	with
0.14285714285714285	the	safety
0.5	changes	in
0.125	of	inhaled
0.5	studies	addressing
0.25	,	the
1.0	these	therapies
1.0	40–50%	.
1.0	(ards)	and
0.2	or	aepo
0.125	.	the
0.2	with	ali
1.0	end	points
1.0	seven	reports
0.125	.	in
0.2	and	standard
0.5	acute	respiratory
0.2	with	an
1.0	examined	for
1.0	modes	of
0.5	inhaled	vasodilators
1.0	vasodilators	can
1.0	guide	to
1.0	oxide	(ino)
0.14285714285714285	the	article
1.0	overall	benefit
0.5	acute	lung
0.5	standard	modes
0.14285714285714285	in	survival
1.0	is	safe
1.0	relevant	studies
0.14285714285714285	in	addition
1.0	ventilator-free	days
1.0	safety	and
1.0	respiratory	distress
1.0	either	ino
0.25	oxygenation	without
0.5	standard	delivery
0.2	to	the
1.0	determine	the
0.5	for	ino
1.0	further	studies
0.125	.	no
1.0	therapies	.
1.0	points	using
1.0	data	,
0.25	,	or
0.2	with	ards
0.125	of	mechanical
0.14285714285714285	the	use
0.5	article	also
1.0	have	been
1.0	this	article
0.2	and	efficacy
1.0	(aepo)	in
1.0	trials	were
1.0	syndrome	(ards)
0.5	article	reviews
0.2	or	attenuation
0.125	of	40–50%
1.0	a	practicable
0.3333333333333333	use	of
0.3333333333333333	aepo	.
1.0	randomized	controlled
1.0	included	for
1.0	mortality	of
1.0	aerosolized	epoprostenol
0.2	and	acute
1.0	differences	have
0.14285714285714285	in	oxygenation
0.125	.	based
0.3333333333333333	ino	reporting
0.2	to	determine
1.0	practicable	guide
1.0	patients	with
0.5	are	conditions
1.0	can	help
0.25	oxygenation	.
0.5	studies	with
0.125	of	these
0.2	to	improve
1.0	application	of
1.0	transiently	improve
0.3333333333333333	use	in
1.0	hypoxemia	associated
1.0	injury	(ali)
0.25	oxygenation	or
0.3333333333333333	ino	or
1.0	also	provides
1.0	days	,
1.0	controlled	trials
1.0	efficacy	of
1.0	lung	injury
0.14285714285714285	the	overall
1.0	reports	of
0.125	.	seven
1.0	survival	,
1.0	attenuation	in
1.0	help	to
1.0	addressing	the
0.2	with	consistent
0.5	clinical	outcomes
1.0	safe	to
0.5	were	examined
0.125	of	aepo
0.3333333333333333	aepo	is
1.0	distress	syndrome
1.0	outcomes	.
1.0	provides	a
1.0	no	differences
0.5	are	needed
0.2	or	clinical
0.2	or	ards
0.2	and	ali
1.0	needed	to
0.14285714285714285	the	treatment
0.5	ards	to
1.0	prospective	randomized
0.5	were	included
1.0	without	hemodynamic
1.0	(ino)	and
1.0	disease	severity
0.2	with	ino
0.125	of	life-threatening
0.125	.	further
1.0	ventilation	are
0.2	to	transiently
0.5	inhaled	nitric
1.0	life-threatening	hypoxemia
0.5	improve	oxygenation
0.5	for	changes
1.0	available	data
1.0	mechanical	ventilation
1.0	reviews	relevant
1.0	nine	prospective
